ImmuneID is a technology company.
ImmuneID has raised $67.0M across 2 funding rounds.
ImmuneID has raised $67.0M in total across 2 funding rounds.
ImmuneID has raised $67.0M in total across 2 funding rounds.
ImmuneID's investors include Advanced Technology Ventures, Aisling Capital, Alta Partners, Chris, Domain Associates, Longwood Fund, Section 32, The Column Group, Third Rock Ventures.
# ImmuneID: Precision Immunology at Scale
ImmuneID is a precision immunology company that has developed a proprietary platform to identify and therapeutically target antibody interactions driving immune diseases.[1] Rather than building a single drug, ImmuneID functions as a technology-enabled discovery engine—using artificial intelligence, next-generation sequencing, and robotic automation to screen billions of antibody-target interactions simultaneously.[1][2] This approach addresses a fundamental bottleneck in drug discovery: identifying high-quality therapeutic targets with precision and speed.
The company serves the broader biopharmaceutical ecosystem by enabling faster, more accurate target identification across multiple disease areas including autoimmunity, severe allergy, oncology, and infectious disease.[2][3] ImmuneID's real value proposition lies in its ability to reduce the time and cost of early-stage drug discovery while simultaneously improving the odds of clinical success through better patient segmentation and disease understanding. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has rapidly attracted top-tier venture capital backing, securing $17 million in seed funding and subsequently raising $50 million in Series A financing.[1][4]
ImmuneID emerged from the laboratories of Harvard Medical School, specifically from the research group of Stephen Elledge, a Lasker Award-winning geneticist and Gregor Mendel Professor of Genetics and Medicine.[2] The founding team includes three scientific co-founders with deep expertise: Stephen Elledge (Harvard), Ben Larman (Johns Hopkins), and Tomasz Kula (Harvard), alongside Michael Mina from Harvard T.H. Chan School of Public Health serving on the scientific advisory board.[2][3]
The company was founded in 2020 by Longwood Fund, a venture capital firm focused on life sciences innovation.[1][2] The founding was catalyzed by years of intensive research and development within the Elledge Lab, which had optimized a massively parallel, multiplexed, and unbiased platform for interrogating the immune system.[2] The core technology—including the VirScan system—leverages advances in DNA synthesis and sequencing to provide high-resolution insight into antibody epitopes relevant for drug development.[3] This academic-to-commercial transition was well-timed: the founding team had already published multiple articles in leading journals validating the platform's robustness and utility, providing immediate credibility with investors and the biotech community.
ImmuneID's competitive moat centers on its aiSPIRE (AI for Screening and Profiling Immune REactivity) platform, which screens billions of antibody-target interactions while applying machine learning to identify disease-driving pathways.[1] The platform combines three critical capabilities: next-generation sequencing for massive parallelization, robotic automation for throughput, and artificial intelligence for pattern recognition and patient stratification.[2] This combination is difficult to replicate because it requires simultaneous expertise in molecular biology, automation engineering, and machine learning—a rare combination in early-stage biotech.
The company directly addresses what Stephen Elledge describes as "a vexing bottleneck in drug discovery"—the identification of high-quality therapeutic targets.[2] Traditional approaches to target identification are slow, biased, and often miss critical disease drivers. ImmuneID's unbiased, high-throughput methodology provides previously unavailable insight into human immune responses throughout disease progression, enabling researchers to identify not just what antibodies matter, but how they correlate with disease course and drug responsiveness.[3]
Rather than being locked into a single disease area, ImmuneID's platform is disease-agnostic. The same underlying technology can be applied to identify harmful antibody targets in allergy and autoimmunity, or helpful antibody targets in oncology and infectious disease.[3] This flexibility reduces execution risk and creates multiple revenue streams as the company can license its discoveries to partners or develop therapeutics internally.
The founding team's academic pedigree—particularly Elledge's Lasker Award and Harvard affiliation—provides immediate credibility with both the scientific community and institutional investors. The company is backed by top-tier biotechnology venture investors including Alexandria Venture Investments, Alta Partners, ARCH Venture Partners, In-Q-Tel, and others.[1] This investor syndicate brings not just capital but strategic networks and operational expertise.
ImmuneID sits at the intersection of three powerful trends reshaping drug discovery: the rise of AI-driven target identification, the democratization of high-throughput biology through automation and sequencing, and the shift toward precision medicine and patient stratification.
The timing is particularly favorable. The cost of DNA sequencing has plummeted over the past decade, making massive-scale antibody screening economically viable. Simultaneously, machine learning has matured to the point where it can extract meaningful patterns from complex immunological data. ImmuneID's founding in 2020 captured this inflection point—the company arrived precisely when the underlying technologies had become powerful enough to solve a problem that had plagued drug discovery for decades.
Beyond its direct impact on its own pipeline, ImmuneID influences the broader biotech ecosystem by establishing a new model for early-stage drug discovery. Rather than following the traditional path of identifying a single target and building a company around it, ImmuneID demonstrates that platform-based discovery—where the company's core value is its ability to generate validated targets across multiple indications—can attract significant venture capital and institutional support. This model is increasingly being adopted across biotech, particularly in areas like immunology, oncology, and infectious disease where antibody biology is central.
The company's work also has implications for how the industry thinks about patient segmentation and personalized medicine. By correlating antibody epitopes with clinical outcomes, ImmuneID enables not just better drug discovery but better patient stratification—identifying which patients are most likely to benefit from specific therapies. This precision approach reduces clinical trial failure rates and accelerates time-to-market.
ImmuneID represents a compelling thesis: that the bottleneck in modern drug discovery is not chemistry or biology, but rather the ability to identify the right targets with precision and speed. By building a platform that solves this problem at scale, the company has positioned itself as a potential infrastructure layer for the entire immunology and oncology drug discovery ecosystem.
Looking ahead, ImmuneID's trajectory will likely follow one of several paths. The company could continue as an independent platform company, licensing discoveries to larger pharma partners while building its own pipeline of therapeutic programs. Alternatively, it could be acquired by a major pharmaceutical company seeking to accelerate its target identification capabilities. A third possibility is that ImmuneID becomes a reference standard for precision immunology, with its platform becoming embedded in how the industry approaches antibody-driven disease.
The key inflection points to watch are: (1) validation of lead therapeutic programs in clinical trials, demonstrating that platform-identified targets translate to efficacy; (2) expansion of the platform to adjacent disease areas beyond immunology; and (3) partnerships or licensing deals that demonstrate the platform's value to the broader biotech and pharma ecosystem.
What makes ImmuneID particularly interesting from an investment perspective is that it operates at the intersection of platform economics and therapeutic upside. Even if the company's internal pipeline underperforms, the platform itself has significant value. Conversely, if the company successfully develops transformational therapeutics, the platform becomes a secondary value driver. This dual-upside structure, combined with the company's strong scientific foundation and well-capitalized position, suggests ImmuneID is well-positioned to influence how precision medicine and drug discovery evolve over the next decade.
ImmuneID has raised $67.0M across 2 funding rounds. Most recently, it raised $50.0M Series A in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $50.0M Series A | Advanced Technology Ventures, Aisling Capital, Alta Partners, Chris, Domain Associates, Longwood Fund, Section 32, The Column Group, Third Rock Ventures | |
| Feb 1, 2021 | $17.0M Venture Round | Advanced Technology Ventures, Chris, Longwood Fund, The Column Group |